Mumbai, May 9 -- Tramadol is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The acquisition of this product adds to Senores' growing portfolio of pain management therapies and is in line with the company's strategic focus on expanding its presence in the U.S. generics market.
According to IQVIA, the market size of Tramadol Tablets in the U.S. was approximately $61.95 million for the 12-month period ending December 2024. As per the specialty data aggregator Symphony, the market was valued at approximately $119.09 million for the 12-month period ending March 2025.
The acquisition will be funded through the initial public offer (IPO) proceeds raised by SP...